Cyclacel
Investors & Media

News

All Releases
View Summary Mechanistic Rationale for CYC065, Cyclacel's CDK2/9 Inhibitor, in Targeted Solid Tumors and Hematological Malignancies Presented at AACR-NCI-EORTC International Conference
Nov 9, 2015
PDF 14.5 KB Add to Briefcase
View Summary Cyclacel Pharmaceuticals to Release Third Quarter 2015 Financial Results
Nov 5, 2015
PDF 12.5 KB Add to Briefcase
View Summary Data to be Presented on CYC065, Cyclacel's CDK2/9 Inhibitor, at AACR-NCI-EORTC International Conference
Oct 26, 2015
PDF 13.6 KB Add to Briefcase
View Summary Cyclacel Doses First Patient in Phase 1 Trial of Its Novel CDK2/9 Inhibitor, CYC065, for the Treatment of Advanced Solid Tumors
Oct 22, 2015
PDF 16.1 KB Add to Briefcase
View Summary Cyclacel Presents Molecular Rationale for Clinical Development of CYC065 CDK Inhibitor in Leukemias and Lymphomas
Sep 17, 2015
PDF 14.7 KB Add to Briefcase
View Summary Cyclacel Pharmaceuticals to Present at Rodman & Renshaw 17th Annual Global Investment Conference
Sep 3, 2015
PDF 11.0 KB Add to Briefcase
View Summary Cyclacel Pharmaceuticals Reports Second Quarter 2015 Financial Results
Aug 11, 2015
PDF 25.7 KB Add to Briefcase
View Summary Cyclacel Pharmaceuticals to Release Second Quarter 2015 Financial Results
Aug 5, 2015
PDF 13.4 KB Add to Briefcase
View Summary First Patient Dosed in IST of CDK Inhibitor Seliciclib in Cushing's Disease, a Serious Endocrine Disorder
Jul 2, 2015
PDF 16.0 KB Add to Briefcase
View Summary Cyclacel & ManRos Therapeutics Announce Licensing & Supply Agreement Regarding Development of Seliciclib in Cystic Fibrosis
Jun 29, 2015
PDF 17.5 KB Add to Briefcase
View Summary Cyclacel Pharmaceuticals to Present at 10th Annual JMP Securities Healthcare Conference
Jun 17, 2015
PDF 11.1 KB Add to Briefcase
View Summary Cyclacel Pharmaceuticals Reports First Quarter 2015 Financial Results
May 12, 2015
PDF 24.3 KB Add to Briefcase
View Summary Cyclacel Pharmaceuticals to Release First Quarter 2015 Financial Results
May 5, 2015
PDF 13.4 KB Add to Briefcase
View Summary Cyclacel's Second-Generation CDK2/9 Inhibitor, CYC065, Demonstrates Therapeutic Potential and Synergy With Other Anti-Cancer Compounds
Apr 20, 2015
PDF 23.5 KB Add to Briefcase
View Summary Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2014 Financial Results
Mar 24, 2015
PDF 27.3 KB Add to Briefcase
View Summary Cyclacel's CYC065 Featured in Presentations at the American Association for Cancer Research Annual Meeting 2015
Mar 20, 2015
PDF 12.6 KB Add to Briefcase
View Summary Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2014 Financial Results
Mar 17, 2015
PDF 13.4 KB Add to Briefcase
View Summary Cyclacel Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Mar 4, 2015
PDF 14.6 KB Add to Briefcase
View Summary Cyclacel Pharmaceuticals Announces Proposed Public Offering of Common Stock
Mar 3, 2015
PDF 14.4 KB Add to Briefcase
View Summary Cyclacel Pharmaceuticals to Present at the 17th Annual BIO CEO & Investor Conference
Feb 3, 2015
PDF 11.1 KB Add to Briefcase
Showing 41-60 of 351 Page: 1 2 3 4 5 6 7 ... 18  Previous 20 | Next 20
Add to Briefcase = add release to Briefcase
Investors & Media